[
  {
    "ts": null,
    "headline": "Should You Still Hold GMED Stock in Your Portfolio?",
    "summary": "Globus Medical is growing musculoskeletal market share with new product launches, strong finances and international expansion plans.",
    "url": "https://finnhub.io/api/news?id=8fcf6d4c60f993cacffa3956e6f6afe028aabf2e30b329af24eb3c14d64331c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768916160,
      "headline": "Should You Still Hold GMED Stock in Your Portfolio?",
      "id": 138187116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Globus Medical is growing musculoskeletal market share with new product launches, strong finances and international expansion plans.",
      "url": "https://finnhub.io/api/news?id=8fcf6d4c60f993cacffa3956e6f6afe028aabf2e30b329af24eb3c14d64331c0"
    }
  },
  {
    "ts": null,
    "headline": "3 takeaways from Boston Scientific’s $14.5B Penumbra deal",
    "summary": "Penumbra is expected to give Boston Scientific more of a presence in the vascular surgery market, with little overlap between the two companies’ products.",
    "url": "https://finnhub.io/api/news?id=b050939c9e6e7cac27695b0098e2a02d1472cd8240298b542087e8afe005088b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768906353,
      "headline": "3 takeaways from Boston Scientific’s $14.5B Penumbra deal",
      "id": 138187736,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Penumbra is expected to give Boston Scientific more of a presence in the vascular surgery market, with little overlap between the two companies’ products.",
      "url": "https://finnhub.io/api/news?id=b050939c9e6e7cac27695b0098e2a02d1472cd8240298b542087e8afe005088b"
    }
  }
]